Alejandro Sánchez Alvarado, PhD
Stowers Institute for Medical Research
Alejandro Sánchez Alvarado, PhD, joined the Stowers Institute for Medical Research in 2011. Sánchez Alvarado received a BS in molecular biology and chemistry from Vanderbilt University in Nashville, TN, and a PhD in pharmacology and cell biophysics from the University of Cincinnati College of Medicine in Cincinnati, OH. He performed postdoctoral and independent research at the Carnegie Institution of Washington, Department of Embryology in Baltimore, MD. In 2002, he joined the faculty of the University of Utah School of Medicine in Salt Lake City where he held the H.A. & Edna Benning Presidential Endowed Chair. In 2005, he was named a Howard Hughes Medical Institute Investigator.
Sánchez Alvarado is a member of the American Academy of Arts and Sciences, and of the Latin American Academy of Sciences, a Kavli Fellow of the National Academy of Sciences USA, a Fellow of the Marine Biological Laboratory in Woods Hole, MA, and a recipient of a National Institutes of Health MERIT award and the EE Just Medal for Scientific Achievement. He has served on numerous scientific advisory committees and boards including the National Advisory Council of the National Institute of General Medical Sciences, National Institutes of Health, and presently serves on the Board of Directors of American Century Investments.
Genome Editing: What, Why and How?
Our ability to change genetic information dates back to our efforts at both plant and animal domestication. Thousands of years of crossing, for example, gave us modern corn from what was a fairly inedible ancestor. Our cattle, poultry, beasts of burden and pets came about from similar technologies of crossing to select specific traits codified by the genomes of the species of interest. The advent of molecular biology towards the end of the 20th century opened a whole new door to accomplish in short order what took our ancestors generations to achieve. And the pace has quickened even more with the discovery and adaptation of a bacterial immune process known as CRISPR/Cas9. In this presentation we will discuss how this technology works, what it is presently being used for and what our collective optimism hopes to accomplish in the near future.